Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People Briefs

This article was originally published in The Gray Sheet

Executive Summary

Medtronic appoints new CFO; EndoChoice elevates William Enquist to chairman post; Andrew Bindman named new Agency for Healthcare Research and Quality director; Nexstim seeks new permanent CEO.

You may also be interested in...



Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win

The neuroscience-focused firm plans a 2022 supplemental NDA for Ingrezza following success in the pivotal KINECT-HD study. The biotech needed an R&D success after recent stumbles.

Antisense Oligonucleotide Clinical Guidance Emphasizes Individualized Nature Of Treatment

US FDA’ s latest ‘n of 1’ guidance describes clinical considerations for INDs to support dosing and monitoring of an individual with a life-threatening genetic disease who is eligible to receive an ASO; recommendations apply only when a few patients may be candidates for treatment.

Minute Insight: Medtronic Brings Hugo RAS To Canada

Health Canada has licensed Hugo for urologic and gynecologic laparoscopic surgical procedures.

Topics

Related Companies

UsernamePublicRestriction

Register

MT034742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel